Published in Bone on September 19, 2005
Fast regulation of AP-1 activity through interaction of lamin A/C, ERK1/2, and c-Fos at the nuclear envelope. J Cell Biol (2008) 1.36
Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling. J Biol Chem (2009) 1.11
A very large number of GABAergic neurons are activated in the tuberal hypothalamus during paradoxical (REM) sleep hypersomnia. PLoS One (2010) 1.00
A novel role of L-serine (L-Ser) for the expression of nuclear factor of activated T cells (NFAT)2 in receptor activator of nuclear factor kappa B ligand (RANKL)-induced osteoclastogenesis in vitro. J Bone Miner Metab (2006) 0.81
Single nucleotide polymorphisms in bone turnover-related genes in Koreans: ethnic differences in linkage disequilibrium and haplotype. BMC Med Genet (2007) 0.77
A Signaling Network Controlling Androgenic Repression of c-Fos Protein in Prostate Adenocarcinoma Cells. J Biol Chem (2016) 0.77
Salt-inducible kinases (SIK) inhibition reduces RANKL-induced osteoclastogenesis. PLoS One (2017) 0.75
Single cell transcriptome analysis of muscle satellite cells reveals widespread transcriptional heterogeneity. Gene (2017) 0.75
Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell (2005) 3.91
The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun (2013) 2.31
Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet (2006) 2.15
Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology (2003) 2.10
Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A (2011) 1.97
Retracted The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome. Cell (2003) 1.88
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood (2005) 1.85
Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev (2004) 1.83
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood (2004) 1.78
Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol (2006) 1.72
Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res (2009) 1.59
Increased arterial carboxyhemoglobin concentrations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2005) 1.57
Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc Res (2005) 1.55
Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res (2007) 1.48
Carbocisteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc (2006) 1.45
Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology (2002) 1.40
Dermatomyositis with peripheral nervous system involvement: activation of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) in vasculitic lesions. Intern Med (2003) 1.40
Effects of rhinovirus infection on the adherence of Streptococcus pneumoniae to cultured human airway epithelial cells. J Infect Dis (2003) 1.35
Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res (2003) 1.32
Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation (2004) 1.32
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood (2002) 1.31
High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation (2004) 1.27
Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. J Bone Miner Res (2004) 1.26
Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem (2004) 1.24
A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res (2015) 1.23
Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem (2005) 1.20
Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci (2008) 1.19
Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab (2005) 1.17
Pin1 down-regulates transforming growth factor-beta (TGF-beta) signaling by inducing degradation of Smad proteins. J Biol Chem (2009) 1.16
Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J Biol Chem (2002) 1.13
Transcriptional induction of FosB/DeltaFosB gene by mechanical stress in osteoblasts. J Biol Chem (2004) 1.12
Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One (2010) 1.11
A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone (2009) 1.09
Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment. Theranostics (2013) 1.07
Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Sci (2009) 1.07
A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J Biol Chem (2004) 1.07
HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol Immunother (2008) 1.07
Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One (2011) 1.06
Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT. Bone (2011) 1.06
Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab (2014) 1.05
Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol (2006) 1.04
Free fatty acid receptors and their role in regulation of energy metabolism. Rev Physiol Biochem Pharmacol (2013) 1.03
Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol (2004) 1.03
Osteoporosis is highly prevalent in Japanese males with chronic obstructive pulmonary disease and is associated with deteriorated pulmonary function. J Bone Miner Metab (2014) 1.02
Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B. J Biol Chem (2007) 0.99
Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study. Osteoporos Int (2004) 0.99
Androgen-androgen receptor system protects against angiotensin II-induced vascular remodeling. Endocrinology (2009) 0.98
The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol (2005) 0.98
Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res (2007) 0.97
Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. Oncol Rep (2006) 0.97
Inorganic phosphate homeostasis in sodium-dependent phosphate cotransporter Npt2b⁺/⁻ mice. Am J Physiol Renal Physiol (2011) 0.96
Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem (2002) 0.96
A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Res (2007) 0.96
Retracted Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol Cell Biol (2002) 0.95
Mechanical stress induces Interleukin-11 expression to stimulate osteoblast differentiation. Bone (2009) 0.94
Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol (2007) 0.94
Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury. Hypertension (2010) 0.94
Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice. Mol Endocrinol (2010) 0.94
Adrenomedullin enhances angiogenic potency of bone marrow transplantation in a rat model of hindlimb ischemia. Circulation (2005) 0.93
Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. Blood (2005) 0.92
Parkin affects mitochondrial function and apoptosis in neuronal and myogenic cells. Biochem Biophys Res Commun (2006) 0.92
Validation of the Japanese Osteoporosis Quality of Life Questionnaire. J Bone Miner Metab (2010) 0.92
Chronic corticosteroid administration causes mitochondrial dysfunction in skeletal muscle. J Neurol (2002) 0.91
Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. J Bone Miner Metab (2008) 0.91
Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study. J Bone Miner Metab (2008) 0.90
Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin Cancer Res (2006) 0.90
Mechanical stress activates Smad pathway through PKCδ to enhance interleukin-11 gene transcription in osteoblasts. PLoS One (2010) 0.90
Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J Atheroscler Thromb (2010) 0.90
Microbial population dynamics during startup of a full-scale anaerobic digester treating industrial food waste in Kyoto eco-energy project. Bioresour Technol (2010) 0.89
Vitamin D insufficiency defined by serum 25-hydroxyvitamin D and parathyroid hormone before and after oral vitamin D₃ load in Japanese subjects. J Bone Miner Metab (2010) 0.89
Diurnal fluctuation of edema synchronized with plasma VEGF concentration in a patient with POEMS syndrome. Intern Med (2002) 0.89
Infective endocarditis caused by lactobacillus. Intern Med (2008) 0.89
Eldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidol. J Bone Miner Metab (2013) 0.89
Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab (2011) 0.89
Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes. Endocr J (2008) 0.88
Concise review: Defining and targeting myeloma stem cell-like cells. Stem Cells (2014) 0.88